Myosin Therapeutics, Inc., a biotechnology company developing novel therapies for cancer and neurological disorders, has ...

A Jupiter company secured millions in a seed funding round backed by Florida-based investors such as DeepWork Capital and the Florida Opportunity Fund.

UMass Lowell Recognized as Top Research Institution with R1 Classification Read More ⁠ ...

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the company will present data on sevasemten, an investigational orally ...

No biological system has been studied by more diverse approaches than the actin-based molecular motor myosin. Biophysics, biochemistry, physiology, classical genetics and molecular genetics have ...

If you make burgers at home, there's a common mistake that people make that results in a tough, cardboard-like burger. Here's ...

Edgewise Therapeutics' stock soars on positive Becker Muscular Dystrophy trial results. Learn why EWTX is a promising buy with derisked programs.

An individual sarcomere contains many parallel actin (thin) and myosin (thick) filaments. The interaction of myosin and actin proteins is at the core of our current understanding of sarcomere ...

LeerinkGlobal Biopharma Conference: Robert I. Blum, President and Chief Executive Officer, and Andrew Callos, Executive Vice President and Chief Commercial Officer, will participate in a fireside chat ...

JUPITER, Fla., Feb. 26, 2025 /PRNewswire/ -- Myosin Therapeutics, Inc., a biotechnology company developing novel therapies for cancer and neurological disorders, has closed its second seed funding ...